Search clinical trials for: "MAX-40279-01" and "Toripalimab"

Total 2573 results

Maxinovel Pty., Ltd.

Recruiting

A Study to Evaluate the Safety and Efficacy of Max-40279 and Toripalimab in Patients With Advanced Solid Tumors

Solid Tumor

China
Maxinovel Pty., Ltd.

Recruiting

A Phase 2 Study to Evaluate the Safety and Efficacy of Max-40279-01 in Patients With Advanced Gastric Cancer or Gastroesophageal Junction Cancer

Gastric Cancer | Gastroesophageal Junction Cancer

China
Maxinovel Pty., Ltd.

Not yet recruiting

A Clincal Study of Max-40279-01 in Patients With Advanced Colorectal Cancer

Metastatic Colorectal Cancer

China
Maxinovel Pty., Ltd.

Recruiting

Study of MAX-40279 in Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)

AML

China
Maxinovel Pty., Ltd.

Recruiting

MAX-40279-01 in Patients With Advanced Solid Tumors

Solid Tumor

China
Maxinovel Pty., Ltd.

Not yet recruiting

A Study of MAX-40279combined With KN046 in Patients With Advanced / Metastatic Solid Tumors

Advanced / Metastatic Solid Tumors
Maxinovel Pty., Ltd.

Recruiting

MAX-40279 in Subjects With Acute Myelogenous Leukemia (AML)

Acute Myelogenous Leukemia (AML)

Australia
Maxinovel Pty., Ltd.

Recruiting

A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Max-40279-01 in Combination With Azacitidine (AZA) in Patients With Myelodysplastic Syndrome (MDS) or Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Acute Myeloid Leukemia | Leukemia | Myelodysplastic Syndrome | Relapsed/Refractory Acute Myeloid Leukemia

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC

Nasopharyngeal Carcinoma | Gastric Adenocarcinoma | Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma

China
Livzon Pharmaceutical Group Inc.

Active, not recruiting

A Preliminary Exploratory Study to Evaluate the Safety and Immunogenicity of Omicron Variant Bivalent Vaccine V-01-B5 (COVID-19)

COVID-19 Pandemic

China
Taizhou Hospital

Not yet recruiting

Toripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small Cell (SCLC)

SCLC | Maintenance Treatment
Sun Yat-sen University

Recruiting

Chidamide Combined With Toripalimab in Sarcoma

Sarcoma

China
Shanghai Hongyitang Biopharmaceutical Technology...

Completed

A Phase IIa Clinical Trial on TSG-01 in the Treatment of Chronic Heart Failure in Patients With Coronary Heart Disease.

Chronic Heart Failure

China
Qilu Hospital of Shandong University

Not yet recruiting

Toripalimab Combined With Anlotinib in Unresectable Locally Advanced or Metastatic Acral Malignant Melanoma

Locally Advanced or Metastatic Acral Malignant Melanoma

China
Sun Yat-sen University

Active, not recruiting

Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)

Nasopharyngeal Carcinoma | Recurrent or Metastatic Nasopharyngeal Carcinoma

China
NYU Langone Health

Completed

Phthalate and Bisphenol Exposure During Minipuberty

Phthalate Exposure | Bisphenol Exposure

United States
RemeGen Co., Ltd.

Recruiting

A Study of RC118 Plus Toripalimab in Patients With Locally Advanced Unresectable or Metastatic Solid Tumors

Advanced Solid Tumor

China
Henan Cancer Hospital

Recruiting

Teripalimab Plus Chemotherapy in Local Advanced Esophageal Cancer

Esophageal Cancer | Squamous Cell Carcinoma | Perioperative Period

China
BioPharmX, Inc.

Completed

BPX-01 Minocycline 1% Topical Gel for Reduction of Propionibacterium Acnes

Acne Vulgaris

United States
Sun Yat-sen University

Recruiting

Anlotinib Combined With Toripalimab in Refractory and Advanced Soft-tissue Sarcoma

Sarcoma,Soft Tissue

China
Sun Yat-sen University

Unknown

Toripalimab as Monotherapy for Patients With Small Cell Carcinoma of Esophagus Who Failed Chemotherapy

Advanced Cancer | Small Cell Carcinoma of Esophagus

China
Shanghai Chest Hospital

Not yet recruiting

Neoadjuvant Therapy of SBRT Sequencial With Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC Patients(neoR-TORCH) (neoR-TORCH)

Stage II-III Non-small Cell Lung Cancer
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

A Clinical Study to Evaluate the Safety and Tolerability of JS001sc in Advanced Nasopharyngeal Carcinoma

Advanced Nasopharyngeal Carcinoma

China
Ruijin Hospital
Guangdong Provincial People's Hospital

Not yet recruiting

Neoadjuvant Toripalimab for Clinically Stage II-IIIB Resectable Non-small Cell Lung Cancer With EGFR Mutation and PD-L1 Positive Expression (TOPLINE)

Carcinoma, Non-Small-Cell Lung

China
Oklahoma State University

Recruiting

Exercise-Induced Gut Permeability in Normal-weight Obesity

Obesity | Normal-weight Obesity

United States
BioPharmX, Inc.

Completed

BPX-01 Minocycline Topical Gel in the Treatment of Acne Vulgaris (OPAL)

Acne Vulgaris

United States
Sun Yat-sen University

Recruiting

Anti-PD-1 Antibody Combined With Histone Deacetylase Inhibitor in Patients With Advanced Cervical Cancer

Cervical Cancer | Cervix Cancer | Cervix Neoplasm

China
Beijing Friendship Hospital

Not yet recruiting

PD-1 Antibody Improve Mixed Chimerism (HLH)

PD-1 Antibody | Mixed Chimerism

China
Shanghai Ninth People's Hospital Affiliated to...

Unknown

High-risk Recurrent or Second Primary HNSCC With PD-1 Antibody Adjuvant After Salvage Surgery(RePASS) (RePASS)

Head and Neck Cancer

China
Crucell Holland BV
The PATH Malaria Vaccine Initiative (MVI); Seattle Children's Research Institute...

Completed

A Study to Assess the Immunogenicity, Tolerability and Safety of a Malaria Vaccine and Also Its Protective Efficacy in a Malaria Challenge Model

Malaria

United States
MC2 Therapeutics

Completed

Evaluation of Potential Phototoxicity Skin Reaction After Use of MC2-01 Cream

Phototoxicity

United States
Fujifilm Pharmaceuticals U.S.A., Inc.

Completed

Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies

AML | MDS | CMML

United States
Sichuan Cancer Hospital and Research Institute

Active, not recruiting

Toripalimab With Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
MC2 Therapeutics

Completed

Evaluation of Potential Development of Photoallergic Skin Reaction After Use of MC2-01 Cream

Photoallergy

United States
Tianjin Medical University Cancer Institute and...

Recruiting

Induction Toripalimab and Chemotherapy in Locally Advanced Cervical Cancer

Cervical Cancer | Immunotherapy | Induction Chemotherapy

China
Hebei Medical University Fourth Hospital

Recruiting

Toripalimab Combined With Radiotherapy and S-1 for Older Patients With Esophageal Cancer (Best-EEC)

Esophageal Carcinoma

China
Wan He

Recruiting

PD-1 Blockade With JS001 Plus Neoadjuvant Chemotherapy for Gastric/Gastroesophageal Junction Cancer (PNACGEC)

Stomach Neoplasms

China
Cancer Hospital of Guangxi Medical University

Recruiting

Concurrent Chemoradiotherapy With Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma: a Prospective, Single-arm, Phase II Trial

Nasopharyngeal Carcinoma | Recurrent Nasopharyngeal Squamous Cell Carcinoma | Toripalimab

China
Sun Yat-sen University

Recruiting

Toripalimab as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors

Solid Tumor | Advanced Cancer

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

Toripalimab or Placebo as Adjuvant Therapy in Hepatocellular Carcinoma After Radical Resection (JUPITER 04)

Hepatocellular Carcinoma

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Toripalimab for Patients With Recurrent Malignant Lymphoma

Malignant Lymphoma

China
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of an Anti-PD-1 mAb for Patients With Advanced Solid Tumors

Lymphoma | Lung Cancer

China
Michele Sayag

Completed

Prevention of Phototoxicities in Patients Undergoing Vemurafenib Treatment

Phototoxicity

France
Shanghai Kanda Biotechnology Co., Ltd.

Recruiting

KD6001 in Combination With Anti-PD-1 Antibody in Patients With Advanced Melanoma

Melanoma

China
Shanghai Junshi Bioscience Co., Ltd.
Sponsor GmbH

Recruiting

A Phase I Clinical Study of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab Injection in Patients With Advanced Solid Tumors

Liver Cancer, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Cervical Cancer, MSI-H Colorectal Cancer

China
Elpiscience Biopharma, Ltd.
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors

Neoplasms | Solid Tumor | Malignant Tumor

China
Sichuan University

Recruiting

ATG-008 Combined With Toripalimab in Advanced Solid Tumors

Advanced Solid Tumor

China
Shanghai Junshi Bioscience Co., Ltd.

Terminated

A Study Explore JS001+JS002 in Patients With Advanced Cancer

Advanced Cancer

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

The Pharmacokinetics and Safety of Single-dose and Parallel Comparisons in Patients With NSCLC Treated With JS001

NSCLC

China
Vejle Hospital

Active, not recruiting

Shared Decision Making With Anal Cancer Patients on Radiation Dose (PC-Anal-01)

Anal Cancer

Denmark

3

Subscribe